Provider Monoclonal Resources

A new monoclonal antibody from Eli Lilly for the treatment of active COVID-19 in non-hospitalized patients was recently given emergency use authorization (EUA). The State of Michigan has received limited doses for distribution to hospitals. Henry Ford has received and will continue to receive scarce allocations.

Because of the limited supply and because of what we know about the effectiveness of this therapy, Henry Ford, in concert with the Food and Drug Administration (FDA) and the state of Michigan, have developed specific protocols for administration to COVID-19 patients in an outpatient setting who meet the criteria.

Please see the following important resources that can assist you with monoclonal antibody eligibility, ordering information, treatment administration and documentation.

Workflow Resources

• Ordering a Therapy Plan for Bamlanivimab Monoclonal Antibody
• Administering a Therapy Plan for Bamlanivimab Monoclonal Antibody
• Personal Protective Equipment Guidance for Bamlanivimab Monoclonal Antibody Administration
• Henry Ford Home Infusion Referral for Monoclonal Antibody Treatment
  
  

Communication Resources:

• Patient FAQs for Monoclonal Antibody Treatment
• Key Messages for Providers and Staff for Monoclonal Antibody Treatment
• Fact Sheet for Patients, Family and Caregivers
• Fact Sheet for Providers